Results 41 to 50 of about 678,599 (312)

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Integrative systems‐level analysis reveals a contextual crosstalk between hypoxia and global metabolism in human breast tumors

Molecular Oncology, EarlyView.
Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam, Salem Chouaib, Mohammad Askandar Iqbal   +2 more
wiley   +1 more source

Vascular Endothelial Growth Factor (VEGF) and Platelet (PF-4) Factor 4 Inputs Modulate Human Microvascular Endothelial Signaling in a Three-Dimensional Matrix Migration Context [PDF]

, 2013
The process of angiogenesis is under complex regulation in adult organisms, particularly as it often occurs in an inflammatory post-wound environment. As such, there are many impacting factors that will regulate the generation of new blood vessels which ...
Adair, Aidoudi, Anastasiadis, Balasubramaniam, Ban, Barrientos, Beauchamp, Bernardini, Bodnar, Bodnar, Brantley-Sieders, Calalb, Campbell, Carmeliet, Carmeliet, Cheng, Chiu, Chung, Dephoure, Eminaga, Fang, Feil, Frey, Fujiwara, George, Gillitzer, Gupta, Hendrix, Hess, Hu, Hu, Huang, Jackson, Kanaji, Kasper, Kaully, Kawauchi, Keeley, Kikawa, Kim, Kirkpatrick, Kobayashi, Kundu, Larsen, Lee, Lim, Liu, Matozaki, Matsui, Mayya, Mehrad, Mendes, Miao, Miao, Miao, Mortensen, Naegle, Newman, Nichols, Noberini, Noberini, Norbury, O'Meara, Pasquale, Patrussi, Perkins, Perretti, Petrai, Platt, Poliakov, Potapova, Radke, Raingeaud, Ravichandran, Ren, Rimchala, Romanova, Rosenkilde, Roux, Saharinen, Sahota, Salcedo, Shao, Sherwood, Shikata, Shults, Singh, Slungaard, Soker, Sotirellis, Spangler, Squire, Su, Sulpice, Szekanecz, Tabruyn, Tcatchoff, Thalhammer, Tremper-Wells, Tsubouchi, Vandercappellen, Vandercappellen, Vindis, Vizcaíno, Walker-Daniels, Welburn, Werdich, Werner, Wykosky, Yancopoulos, Yi, Zhang, Zhang, Zhao   +113 more
core   +1 more source

Vascular Endothelial Growth Factor Expression in the Pathological Angiogenesis in Oral Squamous Cell Carcinoma [PDF]

, 2020
Tumor angiogenesis and tumor progression to late oral squamous cell carcinoma are closely related. Vascular endothelial growth factor (VEGF), a heparin-binding growth factor with mitogenic activity specific for vascular endothelial cells, regulates key ...
Ferrara, Elisabetta, Rapone, Biagio
core   +1 more source

Obesity alters the fitness of peritumoral adipose tissue, exacerbating tumor invasiveness in renal cancer through the induction of ADAM12 and CYP1B1

Molecular Oncology, EarlyView.
Tumor microenvironment drives cancer formation and progression. We analyzed the role of human cancer‐associated adipocytes from patients with renal cell carcinoma (RCC) stratified as lean, overweight, or obese. RNA‐seq demonstrated that, among the most altered genes involved in the tumor–stroma crosstalk, are ADAM12 and CYP1B1, which were proven to be ...
Sepehr Torabinejad, Caterina Miro, Annarita Nappi, Francesco Del Giudice, Annunziata Gaetana Cicatiello, Serena Sagliocchi, Lucia Acampora, Federica Restolfer, Melania Murolo, Emery Di Cicco, Federico Capone, Ciro Imbimbo, Monica Dentice, Felice Crocetto   +13 more
wiley   +1 more source

Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. [PDF]

, 2010
The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and ...
Castro, Susan V., Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +2 more
core   +2 more sources

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis [PDF]

, 2014
Methodology: We have utilized a rational in silico-based approach to demonstrate the design and study of a novel compound that acts as a dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1).
AM Latham, Antony M. Latham, B Apsel, Colin W. G. Fishwick, D Santamaria, Domenico Ribatti, E Schonbrunn, EA Murphy, G Bergers, G Draetta, Gareth W. Fearnley, GI Evan, GJ Howell, GW Fearnley, H Haddad, H Huynh, I Zachary, J Galon, J Kankanala, J Lee, J Pines, Jayakanth Kankanala, JC Tille, JJ Tung, JM Ebos, JW Schmidberger, K Boda, KM Malinda, M Doree, M Mohammadi, MA Ali, MA Branca, Mark T. Kearney, Matthew C. Gage, MP Jacobson, MS Squires, N Ferrara, O Timofeev, P Carmeliet, P Carmeliet, PA Harris, PG Wyatt, Q Wang, R Morphy, RA Friesner, RA Friesner, S Emanuel, S Huang, S Koch, S Koch, S Ponnambalam, Shervanthi Homer-Vanniasinkam, Sreenivasan Ponnambalam, Stephen B. Wheatcroft, T Anastassiadis, T Bashir, TA Halgren, TA Potapova, V Knights, VE Neubrand, ZW Cai   +60 more
core   +2 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source